KR20110016440A - 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체 - Google Patents

연장된 반감기를 가진 제 ⅰⅹ 인자 접합체 Download PDF

Info

Publication number
KR20110016440A
KR20110016440A KR1020107026368A KR20107026368A KR20110016440A KR 20110016440 A KR20110016440 A KR 20110016440A KR 1020107026368 A KR1020107026368 A KR 1020107026368A KR 20107026368 A KR20107026368 A KR 20107026368A KR 20110016440 A KR20110016440 A KR 20110016440A
Authority
KR
South Korea
Prior art keywords
fix
peg
composition
factor
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107026368A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 헨리
Original Assignee
셀틱 파르마 피이지 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀틱 파르마 피이지 엘티디. filed Critical 셀틱 파르마 피이지 엘티디.
Publication of KR20110016440A publication Critical patent/KR20110016440A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020107026368A 2008-04-24 2009-04-24 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체 Ceased KR20110016440A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24
US61/047,544 2008-04-24

Publications (1)

Publication Number Publication Date
KR20110016440A true KR20110016440A (ko) 2011-02-17

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107026368A Ceased KR20110016440A (ko) 2008-04-24 2009-04-24 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체

Country Status (22)

Country Link
US (1) US20110183906A1 (https=)
EP (1) EP2280734B1 (https=)
JP (1) JP2011519833A (https=)
KR (1) KR20110016440A (https=)
CN (1) CN102046205A (https=)
AU (1) AU2009239641B2 (https=)
BR (1) BRPI0911350A2 (https=)
CA (1) CA2722169A1 (https=)
CO (1) CO6300965A2 (https=)
CR (1) CR11763A (https=)
DK (1) DK2280734T3 (https=)
EC (1) ECSP10010632A (https=)
ES (1) ES2466340T3 (https=)
IL (1) IL208908A0 (https=)
MX (1) MX2010011672A (https=)
MY (1) MY158228A (https=)
NI (1) NI201000177A (https=)
NZ (1) NZ588854A (https=)
RU (1) RU2496521C2 (https=)
UA (1) UA101497C2 (https=)
WO (1) WO2009130602A2 (https=)
ZA (1) ZA201007559B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB201007356D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
PL3552619T3 (pl) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
JP2014520094A (ja) * 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
EP2861261A2 (en) * 2012-06-19 2015-04-22 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
HK1213521A1 (zh) 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
MXPA05007151A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP4490369B2 (ja) * 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
KR101207247B1 (ko) * 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
DE602004025157D1 (de) 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
WO2005033140A1 (ja) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 高純度血液凝固ｉｘ因子調製物およびその精製方法
DE602004026897D1 (de) 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
PL1853700T3 (pl) 2005-02-28 2013-05-31 Baxalta Inc Koekspresja przez rekombinowanie podjednostki 1 reduktazy epoksydu witaminy K w celu poprawy ekspresji białka zależnego od witaminy K
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP2975135A1 (en) * 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
KR20090013816A (ko) * 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病ｂ治療剤及びその製造方法

Also Published As

Publication number Publication date
CR11763A (es) 2011-04-26
CN102046205A (zh) 2011-05-04
NZ588854A (en) 2011-12-22
CO6300965A2 (es) 2011-07-21
NI201000177A (es) 2011-08-29
ECSP10010632A (es) 2011-02-28
MX2010011672A (es) 2011-03-02
WO2009130602A3 (en) 2010-02-11
EP2280734A2 (en) 2011-02-09
DK2280734T3 (da) 2014-05-26
AU2009239641B2 (en) 2013-11-07
IL208908A0 (en) 2011-01-31
RU2496521C2 (ru) 2013-10-27
BRPI0911350A2 (pt) 2017-12-05
WO2009130602A2 (en) 2009-10-29
JP2011519833A (ja) 2011-07-14
UA101497C2 (ru) 2013-04-10
MY158228A (en) 2016-09-15
WO2009130602A9 (en) 2010-04-22
US20110183906A1 (en) 2011-07-28
ES2466340T3 (es) 2014-06-10
AU2009239641A1 (en) 2009-10-29
RU2010147813A (ru) 2012-05-27
HK1151986A1 (en) 2012-02-17
ZA201007559B (en) 2012-01-25
EP2280734B1 (en) 2014-02-26
CA2722169A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
KR20110016440A (ko) 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
JP5619630B2 (ja) 結合型第ｖｉｉｉ因子分子
AU2007245190B2 (en) Pegylated factor VIII
JP5876208B2 (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
CN110330563B (zh) 用于出血性疾病治疗的修饰的丝氨酸蛋白酶抑制剂
JP6242819B2 (ja) 長時間作用型凝固因子およびその生成方法
JP7096668B2 (ja) 長時間作用型凝固因子およびその製造方法
BR122016022033B1 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
KR20180083447A (ko) 인자 ⅷ 중합체 접합체
KR20130055620A (ko) 접합된 혈액 응고 인자 VIIa
ES2795439T3 (es) Medicamento para tratamiento terapéutico y/o mejoría de la sepsis
KR20140083035A (ko) 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
HK1151986B (en) Factor ix conjugates with extended half-lives
TWI535454B (zh) 共軛因子viii分子
JPWO2020084853A1 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101124

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130917

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140409

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150908

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151113

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150908

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I